The
subject matter of the present invention is the use of 2-Pentadecyl-2-
oxazoline (also known as PEA-OXA) in association with
butyric acid, in acidic or salified form, in the treatment of
epilepsy and associated psychiatric comorbidities (such as social isolation). In particular, the present invention relates to PEA-OXA for use, in humans and animals, in the prevention and treatment of
epileptogenesis and comorbidities associated with
epilepsy, such as limited social interaction, wherein PEA-OXA is administered in association or in combination with
butyric acid or a salt thereof, wherein said administration is separate, joint, or simultaneous.